Viewing Study NCT05171660


Ignite Creation Date: 2025-12-25 @ 2:08 AM
Ignite Modification Date: 2025-12-26 @ 3:28 AM
Study NCT ID: NCT05171660
Status: RECRUITING
Last Update Posted: 2025-06-15
First Post: 2021-11-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module